UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel Schiff Base Copper Complexes of Quinoline-2 Carboxaldehyde as Proteasome Inhibitors in Human Prostate Cancer Cells

Journal of medicinal chemistry, 2006-11, Vol.49 (24), p.7242-7246

2006

Volltextzugriff (PDF)

Synthesis, Molecular Characterization, and Biological Activity of Novel Synthetic Derivatives of Chromen-4-one in Human Cancer Cells

Journal of medicinal chemistry, 2006-06, Vol.49 (13), p.3800-3808

2006

Volltextzugriff (PDF)

Synthesis, structural properties and insulin-enhancing potential of bis(quercetinato)oxovanadium(IV) conjugate

Bioorganic & medicinal chemistry letters, 2004-10, Vol.14 (19), p.4961-4965

2004

Volltextzugriff (PDF)

Reduction of oxidative stress induced vanadium toxicity by complexing with a flavonoid, quercetin: a pragmatic therapeutic approach for diabetes

Biometals, 2006-12, Vol.19 (6), p.685-693

2006

Volltextzugriff (PDF)

Reaction of (C-(6-aminomethyl-pyridin-2-yl)methylamine)chloroplatinum(ii) with nucleosides and its biological activity

Dalton transactions : an international journal of inorganic chemistry, 2003-01 (2), p.184-188

2003

Volltextzugriff (PDF)

Full mouth rehabilitation by implant supported fixed prosthesis

Contemporary clinical dentistry, 2020-04, Vol.11 (2), p.199-202

2020

Volltextzugriff (PDF)

A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3176-TPS3176

2022

Volltextzugriff (PDF)

Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-01-02-OT2-01-02

2022

Volltextzugriff (PDF)

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211045845-17588359211045845

2021

Volltextzugriff (PDF)

Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3606-3606

2020

Volltextzugriff (PDF)

Abstract P4-01-35: A Phase 1 Study of the Oral CDK7 Inhibitor XL102 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (QUARTZ-101): Initial Results From the Dose-Escalation Stage

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P4-P4-01-35

2023

Volltextzugriff (PDF)

Abstract CT169: First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT169-CT169

2024

Volltextzugriff (PDF)

Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.A078-A078

2019

Volltextzugriff (PDF)

Comparison of Immunogenicity between the Proposed Pegfilgrastim Biosimilar MYL-1401H and Reference Pegfilgrastim

Blood, 2017-12, Vol.130, p.3568-3568

2017

Volltextzugriff (PDF)

SCARRED UTERUS: COMPLICATIONS IN THE SUBSEQUENT PREGNANCIES OF TWO OR MORE CAESAREAN SECTIONS AND THEIR SOCIAL IMPLICATIONS

INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 2023-08, p.44-45

2023

Volltextzugriff (PDF)

Abstract C031: A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.C031-C031

2023

Volltextzugriff (PDF)

Abstract A137: Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.A137-A137

2023

Volltextzugriff (PDF)

A Non-Linear Dimensionality Reduction Approach for Unmixing Hyper Spectral Data

2023 International Conference on Power Energy, Environment & Intelligent Control (PEEIC), 2023, p.1718-1724

2023

Volltextzugriff (PDF)

Interleukin-1-inducible expression of gro-beta via NF-kappa B activation is dependent upon tyrosine kinase signaling

The Journal of biological chemistry, 1993-08, Vol.268 (24), p.18018-18029

1993

Volltextzugriff (PDF)

A Technique for Web Page Ranking by Applying Reinforcement Learning

IJARCCE, 2016-12, Vol.5 (12), p.18-21

2016

Volltextzugriff (PDF)

Full Mouth Rehabilitation by Implant Supported Fixed Prosthesis

Contemporary clinical dentistry, 2020, Vol.11 (2), p.199-202

2020

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(15)

Publikationsform

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(8)
Life Sciences & Biomedicine
(7)
Animals
(4)
Biological And Medical Sciences
(4)
Mice
(4)
Chemistry, Medicinal
(3)
Humans
(3)
Medical Sciences
(3)
Pharmacology & Pharmacy
(3)
Pharmacology. Drug Treatments
(3)
Antineoplastic Agents
(2)
Biochemistry & Molecular Biology
(2)
Cell Line, Tumor
(2)
Chemistry
(2)
Copper
(2)
Drug Screening Assays, Antitumor
(2)
General Aspects
(2)
Male
(2)
Mice, Inbred Balb C
(2)
Organometallic Compounds - Chemical Synthesis
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel Schiff Base Copper Complexes of Quinoline-2 Carboxaldehyde as Proteasome Inhibitors in Human Prostate Cancer Cells

Synthesis, Molecular Characterization, and Biological Activity of Novel Synthetic Derivatives of Chromen-4-one in Human Cancer Cells

Synthesis, structural properties and insulin-enhancing potential of bis(quercetinato)oxovanadium(IV) conjugate

Reduction of oxidative stress induced vanadium toxicity by complexing with a flavonoid, quercetin: a pragmatic therapeutic approach for diabetes

Reaction of (C-(6-aminomethyl-pyridin-2-yl)methylamine)chloroplatinum(ii) with nucleosides and its biological activity

Full mouth rehabilitation by implant supported fixed prosthesis

A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study

Abstract P4-01-35: A Phase 1 Study of the Oral CDK7 Inhibitor XL102 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (QUARTZ-101): Initial Results From the Dose-Escalation Stage

Abstract CT169: First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors

Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies

Comparison of Immunogenicity between the Proposed Pegfilgrastim Biosimilar MYL-1401H and Reference Pegfilgrastim

SCARRED UTERUS: COMPLICATIONS IN THE SUBSEQUENT PREGNANCIES OF TWO OR MORE CAESAREAN SECTIONS AND THEIR SOCIAL IMPLICATIONS

Abstract C031: A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer

Abstract A137: Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers

A Non-Linear Dimensionality Reduction Approach for Unmixing Hyper Spectral Data

Interleukin-1-inducible expression of gro-beta via NF-kappa B activation is dependent upon tyrosine kinase signaling

A Technique for Web Page Ranking by Applying Reinforcement Learning

Full Mouth Rehabilitation by Implant Supported Fixed Prosthesis

Suchergebnisse filtern